Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.

Trial Profile

Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms CHOP-OR
  • Most Recent Events

    • 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 May 2015 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
    • 07 Jan 2015 Accrual to date is 107% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top